Q-omics provides the consensus-scored GRIK5 profile across patient tissues and cancer cell-line models. GRIK5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRIK5 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, GRIK5 RNA expression shows 18,026 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where GRIK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIK5 survival associations across molecular data types. GRIK5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIK5 RNA expression–survival associations across cancer types. High GRIK5 expression shows unfavorable associations in ACC, KIRC, KIRP, COAD, LUAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRIK5 RNA expression.
This table summarizes GRIK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRIK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIK5 shows lower tumor expression in KIRC, COAD, BLCA, KICH, UCEC and KIRP. The KIRC box plot shows higher GRIK5 RNA expression in normal versus tumor tissue (log2 FC = −3.143, t-test p < 0.001).
This table shows molecular features associated with GRIK5 in patient tissues and cancer cell lines. In patient samples, GRIK5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
